Jonathan Havel

Jonathan Havel has significant experience in the field of scientific research. Jonathan is currently working as a Senior Scientist at Volastra Therapeutics since November 2021. Prior to this, they held the position of Scientist II at the same company from February 2021 to November 2021. Before joining Volastra Therapeutics, Jonathan worked as a Principal Scientist at Loxo Oncology at Lilly from September 2020 to February 2021. Jonathan also worked as a Scientist at Eli Lilly and Company from December 2019 to September 2020. Jonathan's research experience includes roles at Memorial Sloan Kettering Cancer Center, where they worked as a Research Associate from October 2019 to December 2019 and as a Research Scholar from August 2014 to September 2019, under the guidance of Timothy Chan, M.D., Ph.D. Jonathan also worked as a Postdoctoral Fellow at Emory University from June 2013 to June 2014. Jonathan's academic journey began at Emory University, where they pursued their Ph.D. and served as a Graduate Student under the supervision of Haian Fu, Ph.D., from June 2006 to April 2013. Prior to that, they gained industry exposure through internships at Merck in 2005 and 2004, and at Colgate Palmolive in 2003.

Jonathan Havel completed their undergraduate studies at Lehigh University from 2001 to 2005, where they obtained a Bachelor of Science degree in Biochemistry. Jonathan then pursued further education at Emory University from 2006 to 2013, earning a Doctor of Philosophy (Ph.D.) in Molecular and Systems Pharmacology. Additionally, they participated in the AACR workshop, although the specific duration and degree acquired during this workshop were not provided.